The advisory board brought together renowned hematologists and oncologists to discuss the latest developments in the treatment of Acute Myeloid Leukemia (AML) with a focus on FLT3 inhibitors. The participants had the opportunity to gain insights into the latest clinical trials and their implications for the management of AML patients.

We are committed to organizing more such events in the future and hope to continue providing valuable educational opportunities for healthcare professionals.

Stay tuned for updates on our upcoming events!